GREY:LXXGQ - Post by User
Post by
Roadster2on Jan 28, 2020 3:43pm
148 Views
Post# 30610453
Dr. Regan at his best -----Audio
Dr. Regan at his best -----Audio28-Jan-2020:09:30:00, LexaGene Discusses The Company's 2020 Commercialization Strategy with The Stock Day Podcast Phoenix, Arizona--(Newsfile Corp. - January 28, 2020) - The Stock Day Podcast welcomed LexaGene Holdings Inc. (OTCQB: LXXGF) ("the Company"), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. CEO and Founder of the Company, Dr. Jack Regan, joined Stock Day host Everett Jolly. Dr. Regan began the interview by sharing background information about himself and the Company. "While working at Lawrence Livermore National Laboratory, I filed for patent protection to cover a new design for an instrument I felt had a lot of advantages over the instrument we developed for the Department of Homeland Securitys BioWatch Program. LexaGene is now commercializing the novel design captured in those patents," shared Dr. Regan. He then explained how he is using his previous experience helping a startup company launch their product and get acquired to help LexaGene grow to become a successful company. Jolly then commented on the outbreak of the coronavirus, and asked how the Companys technology could be used to detect similar illnesses in the future. "LexaGene is a med-tech device company. We have built a fully automated genetic analyzer that is exceptionally well suited for detecting infectious diseases," explained Dr. Regan. He then expanded on the coronavirus and how the Companys technology is designed to detect similar outbreaks. "Our technology is designed to be placed at the point of care, so in this case it would ideally be placed at airports," said Dr. Regan, adding that this practice would help limit the spread of the disease. "The reason our technology is so well suited for this is that it accepts liquid tests that can very easily be developed and shipped," said Dr. Regan. "The instrument does all of the hard work in terms of analyzing the sample, and more importantly can identify the coronavirus as well as other common respiratory viruses," he added. Dr. Regan then expanded on the Companys LX2 Analyzer. "At its core it is a genetic analyzer," said Dr. Regan, adding that the device is designed to receive a sample and detect its pathogens. "The companion animal space, dogs and cats, is a huge market which right now has effectively no competition in it," said Dr. Regan. "We like to not only identify what is causing the infection, but we also look to inform on how best to treat the infection," explained Dr. Regan, adding that the device is capable of determining whether or not the pathogen is resistant to commonly prescribed antibiotics. "This allows for a much higher quality of care and ultimately a lower cost of care," said Dr. Regan. Dr. Regan also commented, "Were also looking at the food safety space, as the industry is in need of innovative solutions." Jolly then asked about the progress of the Companys device, as well as their timeline for monetization. Dr. Regan shared that the Company is currently in the stage of finalizing the instrument for commercial sale. "We expect by the end of March to be finalizing that design, and once we finalize the design we start the manufacturing process with the expectation of having our first instrument sales in the summer," said Dr. Regan. Jolly then inquired about the Companys goals and vision over the next twelve months. "Its an exceptionally exciting time for the company," said Dr. Regan. "Now we have enough capital to start selling our technology," he shared. "We expect this will result in a significant inflection point in our stock price," said Dr. Regan. He then discussed numerous exit strategies for the Company, including staying independent and uplisting to the NASDAQ, licensing out a market vertical to a strategic partner, or following an acquisition strategy. "All three of those are certainly possibilities in the future," said Dr. Regan. "There is a lot of excitement over what were building, we know theres demand, and were looking forward to providing instruments in the near future," closed Dr. Regan. To hear Dr. Jack Regans entire interview, follow the link to the podcast here: audioboom.com/posts/7489378-lexagene-dis...he-stock-day-podcast Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the companys message board at investorshangout.com/